Anti-IL-23 heterodimer specific antibodies

US9127057B2 · kind B2 · utility

Assignee

• TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · AU

Inventors

• Adam Clarke · Chatswood, AU
• Anthony G. Doyle · Chatswood, AU
• Matthew Pollard · Chatswood, AU
• Stephen Tran · Parramatta, AU

Key dates

• Filing date: Jul 20, 2011
• Grant date: Sep 8, 2015
• Expiry date: Jan 2, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.